Lapatinib Completed Phase 2 Trials for Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Salivary Gland Cancer / Stage IV Verrucous Carcinoma of the Oral Cavity / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage IV Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Stage IV Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Salivary Gland Squamous Cell Carcinoma / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01044433Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck